FR0011184241 - Common Stock

Overall **ADOC** gets a fundamental rating of **2** out of 10. We evaluated **ADOC** against 73 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **ADOC** have multiple concerns. **ADOC** has a valuation in line with the averages, but it does not seem to be growing.

In the past year **ADOC** has reported a negative cash flow from operations.

In the past 5 years **ADOC** always reported negative net income.

With a **Return On Assets** value of **-84.80%**, **ADOC** is not doing good in the industry: **77.94%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -84.8% | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)-61.02%

ROA(5y)-52.94%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

With a decent **Gross Margin** value of **64.42%**, **ADOC** is doing good in the industry, outperforming **70.59%** of the companies in the same industry.

The **Profit Margin** and **Operating Margin** are not available for **ADOC** so they could not be analyzed.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 64.42% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

The number of shares outstanding for **ADOC** has been increased compared to 1 year ago.

Compared to 5 years ago, **ADOC** has more shares outstanding

Compared to 1 year ago, **ADOC** has an improved debt to assets ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | N/A | ||

Altman-Z | -1.69 |

ROIC/WACCN/A

WACC8.14%

A Quick Ratio of **1.01** indicates that **ADOC** should not have too much problems paying its short term obligations.

The **Quick ratio** of **ADOC** (**1.01**) is worse than **72.06%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.02 | ||

Quick Ratio | 1.01 |

The earnings per share for **ADOC** have decreased strongly by **-148.31%** in the last year.

The Revenue for **ADOC** have been decreasing by **-46.13%** on average. This is quite bad

EPS 1Y (TTM)-148.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.04%

Revenue 1Y (TTM)-81.22%

Revenue growth 3Y36.74%

Revenue growth 5Y-46.13%

Sales Q2Q%-87.24%

Based on estimates for the next years, **ADOC** will show a small growth in **Earnings Per Share**. The EPS will grow by **0.53%** on average per year.

EPS Next Y47.15%

EPS Next 2Y15.82%

EPS Next 3Y0%

EPS Next 5Y0.53%

Revenue Next Year68.06%

Revenue Next 2Y35.4%

Revenue Next 3Y31.04%

Revenue Next 5Y23.43%

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

With a **Price/Forward Earnings** ratio of **1.52**, the valuation of **ADOC** can be described as very cheap.

95.59% of the companies in the same industry are more expensive than **ADOC**, based on the **Price/Forward Earnings** ratio.

When comparing the **Price/Forward Earnings** ratio of **ADOC** to the average of the S&P500 Index (**21.99**), we can say **ADOC** is valued rather cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 1.52 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.82%

EPS Next 3Y0%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**ADOCIA SAS**

EPA:ADOC (9/16/2024, 11:49:42 AM)

**5.615**

**+0.04 (+0.81%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap84.45M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 1.52 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -84.8% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 64.42% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.09

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.02 | ||

Quick Ratio | 1.01 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-148.31%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y47.15%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-81.22%

Revenue growth 3Y36.74%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y